Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma

Ticker(s): RLAY

Who's the expert?

Institution: Baptist Health South Florida

Board-certified in hematology and oncology and works as a community hematologist and medical oncologist
treats 15 patients with Cholangiocarcinoma
familiar with RLAY data and familiar with the results from the Phase 2 FOENIX*-CCA2 trial of Lytgobi

Interview Goal

This conversation will be focused on the potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, and the results from the ReFocus Phase 1/2 Study of RLY-4008 in cholangiocarcinoma which were presented at ESMO in September of 2022.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.